一分钟看懂
这是一项关于结直肠癌的II 期 / III 期研究,登记的药物或干预包括Cetuxima-β;Envafolimab;mFOLFOX6,当前状态为尚未开始招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Cetuxima-β;Envafolimab;mFOLFOX6 · II 期 / III 期
登记条件中文摘要
年龄范围:18岁及以上
登记的基本范围为不限性别,年龄18岁及以上;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Medical Oncology,Sun Yat-sen University Cancer Center · 广州
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- * Patients are eligible for the study if they meet all of the following criteria:
- 1. Prior to enrollment, the participant is required to sign a written informed consent form.
- 2. Participants should be above 18 years,regardless of gender.
- 3. Histopathologically confirmed untreated advanced colorectal adenocarcinoma.
- 4. Tumors with RAS (KRAS, NRAS, HRAS) and BRAF wild-type, MSS phenotype, excluding appendiceal or anal cancer. All listed codons must be wild-type: KRAS: Exons 2, 3, 4 (Codons 12, 13, 59, 61, 117, 146) ; NRAS: Exons 2, 3, 4 (Codons 12, 13, 59, 61, 117, 146)
- 5. Imaging (enhanced CT/MRI/PET-CT) confirms advanced/metastatic colorectal cancer with measurable lesions according to RECIST v1.1.
- 6. No prior systemic therapy for advanced/metastatic colorectal cancer, including chemotherapy, EGFR inhibitors (cetuximab, panitumumab), VEGF inhibitors (bevacizumab), and immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4). Adjuvant/neoadjuvant chemotherapy within 6 months before recurrence/metastasis is considered first-line therapy.
- 7. ECOG PS score 0-1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT06959693;登记信息更新于 2025-05-06;本站同步于 2026-11-21。